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EFFICIENCY OF NEUROPROTECTIONS AT 
EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS ON THE 
BACKGROUND OF THERAPY BY METHYLPREDNISOLONE
Oleksandr Nefodov, MD,
Department of General and Clinical Pharmacy,
Hanna Frolova,
Iryna Prydius,
Roman Malchugin,
Department of Clinical Anatomy, Anatomy and Operative Surgery,
SE “Dnepropetrovsk Medical Academy of the Ministry of Healht of Ukraine”
Annotation. A comparative analysis of the neuroprotective effect of Citicoline, Neurovitan 
and α-lipoic acid on the model of experimental equivalent of multiple sclerosis in rats under 
baseline hormone therapy with methylprednisolone (Solu-Medrol) was conducted. Experimental 
allergic encephalomyelitis (EAE) was developed for 9 - 11 days after inoculation of 
encephalitogenic mixture in 92% of the rats of the control group. Injection of Solu-Medrol (SM, 
3.4 mg / kg intravenously over a week) prevented the development of EAE in 20% of animals from 
infected rodents and significantly reduced the severity and duration of neurological disorders, in 
2 - 3 times (compared with control) reducing the average cumulative index and duration of the 
disease. The animals treated with Citicoline (500 mg / kg) in a course of hormone therapy SM 
EAE developed only after completion of drug administration (19 - day 20), leaking momentarily 
(average 5 days) and mild (average cumulative index 6.6). High efficiency of Citicoline with 
EAE mediated likely to continue internal and external (cytoplasmic and mitochondrial) neuronal 
membranes due, on the one hand, the weakening of the activity of phospholipase A2 activation 
and neuronal mitochondrial cytochrome oxidase, and the other - the inhibition of glutamate-
induced apoptosis.
Key words: multiple sclerosis, experimental allergic encephalomyelitis, methylprednisolone, 
neuroprotection, Citicoline, Berlitione, Neurovitan. 
Formulation of the problem. Multiple sclerosis (MS) is a severe demyepinizing 
disease of the central nervous system that occurs as a result of the development of 
autoimmune reactions to myelin proteins with subsequent axonal damage to neurons of 
varying degrees [1]. MS is one of the socially significant problems of modern neurology, 
which is determined by its prevalence, the unpredictability of the course, the defeat 
mainly of young people of working age and frequent disability [2].
The generally accepted model of MS in laboratory animals is experimental 
allergic encephalomyelitis (EAE), which has clinical manifestations and pathogenetic 
mechanisms similar to multiple sclerosis [3].
The main standard method of treating MS is the use of intravenous corticosteroid 
regimens in pulse doses: the appointment of pulse therapy with methylprednisolone is 
considered to be recognized. Methylprednisolone (solu-medrol) usualy injects in a dose 
of 500-1000 mg in 200-400 ml of solution NaCL 0,9% intravenously drip of 25-30 drops 
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per minute 1 time per day. Duration of the course is 3-7 days   [4].
However, despite extensive research, the PC continues to be a problem with many 
unresolved issues. This applies not only to the origin and essence of the disease, but also 
to its clinic, which, it would seem, has been adequately studied [5].
The desire to increase the effectiveness of the treatment of multiple sclerosis has 
led to the development and application of new universal therapeutic approaches to 
the treatment of MS, one of which is neuroprotection aimed at regulating the balance 
of immune and neurotrophic factors, remyelination processes. The feasibility of its 
appointment is determined by the need to maintain axon function and prevent the 
development of axonopathy. The need for neuroprotection is due to damage to both 
myelin sheaths of nerve fibers and the neurons themselves (this leads to the atrophy of 
brain matter), as well as oligodendrocytes (glial cells that support the maintenance and 
reproduction of myelin) [6].
Given the current level of development of knowledge about neuroprotection in MS, 
the optimal neuroprotective therapy in the treatment of this disease from the standpoint 
of practical neurology is carried out by using the following neuroprotective complex [7]:
- anti-inflammatory therapy: TNFa antagonists (trental);
- trophic factors (cerebrolysin);
- inhibition of glutamate excitotoxicity (amantadine - PC-Merz);
- antioxidant therapy: α-lipoic acid, cerebrolysin;
- remyelinating therapy: immunoglobulins, "B" -vitamin complexes.
The use of components of the neuroprotective antioxidant complex inhibits the 
progression of MS, slowing the rate of apoptosis of neurons and oligodendrocytes, as 
well as reducing the intensity of damage to myelin by free radicals, antibodies, and 
inflammatory cytokines [6; 7].
To evaluate the effectiveness of neuroprotective therapy of experimental allergic 
encephalomyelitis in the conditions of basic therapy with solu-medrol. For this, a 
comparative analysis of the protective effect of citicoline, neurovitan, and α-lipoic acid 
was carried out on an EAE model in rats with methylprednisolone.
Materials an Methods. Prior to commencement of work, the bioethics commission 
approved a protocol for upcoming studies. According to the requirements of GLP and 
the European Convention for the Protection of Vertebrate Animals, which are used for 
experimental and other purposes, all procedures related to keeping animals, humane 
handling and their use in an experiment are agreed.
The animals were kept under standard conditions with a day-night light regime of 
12 hours / 12 hours at an air temperature of 20 - 220 C with free access to water and 
food. EAE was induced by a single subcutaneous injection of an encephalitogenic mixture 
(EGM) in complete Freund's adjuvant (CFA) based on 100 mg of homologous spinal cord 
homogenate; 0.2 ml of CFA (the content of killed mycobacteria 5 mg / ml) and 0.2 ml of 
physiological saline per animal. EGM was introduced into the base of the tail under light 
ether anesthesia in a volume of 0.4 ml [8]. Immunized animals were divided into 5 groups: 
I - animals with EAE (control), n = 12; II - EAE + solu-medrol (SM: 3.4 mg / kg), n = 10; 
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ІІІ - EAE + SM + neurovitan (25 mg / kg in terms of octothiamine), n = 8; IV - EAE + SM 
+ citicoline (500 mg / kg), n = 8; V - EAE + SM + berlition (50 mg / kg α-lipoic acid), n = 8.
Solu-medrol was injected  to animals of groups II – VI according to the clinical 
algorithm for the use of the drug [4] at the rate of 3.4 mg / kg into a vein dropwise in the 
volume of physiological saline equal to 1/10 of BCC [9] for a week. In rodents of the 
III – VI groups, additionally, against the background of basic hormone therapy, the test 
substances were administered intragastrically once a day from the second to the 16th 
day after the induction of EAE (latent phase + clinical phase until the end of the peak of 
the disease). The control group consisted of animals with induced EAE (group I), which 
received distilled water intragastrically for 16 days.
Daily for a month (the average duration of EAE), animals were weighed and their 
neurological status was assessed: the time of onset of the disease, its duration and severity 
of neurological disorders were recorded, which was evaluated in points by the clinical 
index. The clinical index (Clin-I) was determined on a scale: muscle weakness of one 
limb - ½ point, paresis - 1 point, paralysis - 1 ½ point. When several extremities were 
involved in the process, the points were summarized. Absence of violations was taken 
as 0 points, fatal outcome - 6 points. Animals with a clinical index of ½ - 2 ½ points 
were considered easily ill; 3 - 6 points corresponded to the severe course of EAE. For an 
integrative assessment of EAE severity for each animal, a cumulative index (Cumul-I) 
was calculated - the sum of individual clinical indices for the period of the disease [10]
To assess the effectiveness of the protective effect of the studied drugs on the EAE 
model for each group of rats, we calculated: 1) the duration of the latent period; 2) 
the total number of sick and seriously ill rats (in% of the number in the group); 3) the 
average clinical index at the peak of the disease; 4) the average cumulative index of the 
disease; 5) the average duration of the disease. All indicators were compared with the 
corresponding animals of the control group and the group receiving basic therapy with 
solu-medrol.
Digital experimental data were processed by the method of variation statistics using 
personal computer equipment - Intel Pentium-IV and the statistical analysis program 
AnalystSoft, StatPlus. Version 2006 [11]. The mathematical processing of the obtained 
data included the calculation of arithmetic mean values (M), their errors (± m).
A comparative analysis of the clinical and cumulative index was carried out using 
the non-parametric Mann-Whitney test. To assess the significance of differences in the 
shares of patients and seriously ill rats compared with the control, a more accurate Fisher 
test was used, and for analysis of the latent period and EAE duration, the Student’s 
criterion with Bonferroni correction was used for multiple comparisons.
Main results of the study. The results of the studies indicate that under conditions 
of a single subcutaneous inoculation of encephalitogenic mixture (EGM)in Freund's 
complete adjuvant in animals of the control group, the development of neurological 
disorders of varying severity was recorded; a fatal outcome of the disease was observed 
in one of 12 rodents (8.3%). In the area of inoculation, manifestations of inflammation 
were noted that persisted for more than 20 days.
Modern Science — Moderní věda 2020 № 3
124
After EAE induction in rats of the control group, the first neurological symptoms 
of the disease were recorded on days 9–11. The peak of clinical manifestations of 
encephalomyelitis in most animals developed on days 12-14 and lasted an average of 
4 days; the duration of EAE was 16.4 + 1.8 days with an average cumulative index of 
27.2 points.
At the peak of the clinical manifestations of EAE, the number of animals with a 
clinical index of ½ - 2 ½ points was 41.7% of rats, which corresponded to a mild disease, 
and severe EAE was observed in 58.3% of rodents (clinical index 3 - 6 points).
An analysis of the obtained experimental data established that the dynamics and 
severity of the development of neurological disorders corresponded to the manifestations 
of EAE described earlier by us or other authors [12; thirteen].
The injection of solu-medrol (3.4 mg / kg into a vein drip during the week) eliminated 
lethal outcomes, completely prevented the development of neurological disorders in 
20% of animals, and also reduced the number of rodents with severe EAE to 30%.
The course application of neurovitan (25 mg / kg in terms of octothiamine) from the 
second to the 16th day after inoculation of EGM with solu-medrol therapy prevented the 
development of EAE in only 25% of animals with a mild course of the disease, without 
significantly changing the duration of the latent period of EAE compared with SM group.
At the same time, neurovitan reduced, on average, 1.1-1.2 times the clinical index 
at the peak of pathology, as well as the cumulative index and duration of the disease 
compared with the group receiving basic hormone therapy.
The therapeutic effect of neurovitan in relation to the manifestations of experimental 
allergic encephalomyelitis in the conditions of basic therapy with solu-medrol is mediated 
by a high-dose complex of B vitamins in its composition. This ensures the development of 
neuroprotective, antioxidant and trophic, promoting remyelination effects. The property 
of this combination is based on the pharmacological effects characteristic of high doses 
of these vitamins, and does not depend on their deficiency. Obviously, octothiamine, 
by enhancing energy supply in the form of ATP, supports axoplasmic transport, while 
pyridoxine is involved in the synthesis of transport proteins, and cyanocobalamin 
provides the delivery of fatty acids for cell membranes and myelin sheath [14].
The combined use of the antioxidant berlition (50 mg / kg α-lipoic acid) and 
methylprednisolone completely prevented the development of EAE in 25% of animals 
with mild disease. In other rodents, administration of the drug against the background 
of basic hormone therapy moderately weakened the severity and duration of EAE: the 
clinical index at the peak of pathology decreased by 19%, the cumulative index by 17%, 
and the duration of EAE by 1.3 times compared with the group treated with solu-medrol.
Compared with mono-injection of glucocorticoid, the combined use of citicoline 
and methylprednisolone more strongly reduced the severity of neurological disorders. 
In particular, in this series of studies, the clinical index at the peak of EAE decreased by 
38%, the cumulative index of the disease was reduced by 30%, and the duration of EAE 
was shortened from 8.4 to 5 days compared with the group receiving basic hormone 
therapy.
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Exogenous citicoline, being a neuroprotective agent, is involved in the biosynthesis 
of membrane phospholipids of neurons, primarily phosphatidylcholine (lecithin). 
Phospholipids form the structural and functional basis of neural membranes that support 
the activity of nerve cells and the brain as a whole (maintaining the ionic balance 
and activity of membrane-bound enzymes, providing a nerve impulse, etc.). When 
exogenously administered, citicoline is rapidly hydrolyzed in the body to circulating 
cytidine and choline, of which, after absorption into the systemic circulation, CDP-
choline is synthesized. The main mechanism of action of citicoline, which determines its 
neuroprotective properties, is the preservation of the external and internal (cytoplasmic 
and mitochondrial) neuronal membranes, primarily by attenuating the activity of 
phospholipase А2, activation of neuronal mitochondrial cytochrome oxidases and 
inhibition of glutamate-induced apoptosis [17; 18].
Thus, citicoline, which most effectively prevents the development of neurological 
disorders and is statistically significant, reduces by 3.3 to 4 times (p <0.05) compared 
with the control group, the most optimal neuroprotection for EAE under conditions of 
therapy with solu-medrol and the duration of the experimental equivalent of multiple 
sclerosis in animals. The moderate severity of the therapeutic effect of berlition and 
neurovitan in our experimental conditions, obviously, indicates the need for a longer 
course of application of these components of antioxidant and remyelinating therapy.
Conclusions:
-  inoculation of the encephalitogenic mixture on days 9–11 in 91.7% of the animals 
of the control group causes the development of EAE, characterized by a severe and 
prolonged course;
-  course use of citicoline, neurovitan and α-lipoic acid in EAE under the conditions 
of basic therapy with solu-medrol to various degrees prevents the development of the 
disease; however, in diseased animals, EAE occurs briefly and mainly in mild form;
- the ability to prevent the development of neurological disorders and reduce the 
severity and duration of the experimental equivalent of multiple sclerosis decreases in 
the series citicoline (500 mg / kg)> berlition (50 mg / kg)> neurovitan (25 mg / kg in 
terms of octothiamine).
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